ストックスクリーナーアプリを入手
0.00
100.00%
-13.60
アフターアワーズ：
13.26
13.26
+
Pieris Pharmaceuticals Inc (PIRS) 最新ニュース
Press Release Distribution & PR Platform - ACCESS Newswire
(PVLA) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Ebenbuild Contributes Cutting-Edge Digital Lung Simulations to Pulmonary Fibrosis Drug Development - The Manila Times
Pieris Pharmaceuticals To Host Third Quarter 2021 Investor Call and Provide Corporate Update on November 2, 2021 - ACCESS Newswire
Palvella Therapeutics Reports 2024 Financial Results and Advances Rare Disease Pipeline - MyChesCo
Asthma Market to Reach New Heights in Growth by 2034, - openPR.com
PALVELLA THERAPEUTICS, INC. SEC 10-K Report - TradingView
Palvella Therapeutics (PVLA) to Release Earnings on Monday - Defense World
(PVLA) Technical Data - news.stocktradersdaily.com
Shane Olwill joins Asgard from Pieris - The Pharma Letter
Public-Private Collaborations Drive Advancements In Anemia And Blood Disorder Drug Development: Key Trend T... - WhaTech
Pieris Pharmaceuticals stock soars to 52-week high of $29.01 - Investing.com
HER2+ Gastric Cancer Market to Witness Upsurge in Growth During the Forecast Period (2024-2034), Examine DelveInsight - The Globe and Mail
Pieris Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Pieris Pharmaceuticals stock hits 52-week high at $22.56 By Investing.com - Investing.com Canada
Pieris Pharmaceuticals stock hits 52-week high at $22.56 - Investing.com
Pieris Pharmaceuticals to Host Full-Year 2019 Investor Call and Corporate Update on March 12, 2020 - ACCESS Newswire
Pieris Pharmaceuticals to Present at the 2019 H.C. Wainwright Global Life Sciences Conference - ACCESS Newswire
Palvella Therapeutics and Pieris Pharmaceuticals Finalize Merger to Focus on Rare Disease Treatments - MSN
Pieris Pharmaceuticals to Host Third Quarter 2020 Investor Call and Corporate Update on November 4, 2020 - ACCESS Newswire
Pieris Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update - ACCESS Newswire
Canaccord Genuity Initiates Palvella Therapeutics at Buy With $39 Price Target -February 20, 2025 at 07:44 am EST - Marketscreener.com
Palvella Therapeutics closes on Pieris merger; completes nearly $80M private placement - Pennsylvania Business Report -
TD Cowen Initiates Palvella Therapeutics at Buy With $44 Price Target -February 05, 2025 at 07:50 am EST - Marketscreener.com
Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific - ACCESS Newswire
Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential - ACCESS Newswire
Pieris Pharmaceuticals Announces PRS-220 Presentation at ERS Highlighting Preclinical Data for CTGF Inhibitor - ACCESS Newswire
Research Analysts Issue Forecasts for PVLA FY2025 Earnings - Defense World
Palvella reports positive phase 2 study on QTORIN rapamycin for rare skin disease - Investing.com India
Palvella reports positive phase 2 study on QTORIN rapamycin for rare skin disease By Investing.com - Investing.com South Africa
StockNews.com Begins Coverage on Pieris Pharmaceuticals (NASDAQ:PIRS) - Defense World
Pieris Pharmaceuticals (NASDAQ:PIRS) Now Covered by Analysts at StockNews.com - Defense World
Palvella Therapeutics stock gains attention with Phase 3 trial data expected in early 2026 - Investing.com Canada
Pieris Pharmaceuticals (NASDAQ:PIRS) Coverage Initiated at StockNews.com - Defense World
Twelve option delistings on December 23rd - TipRanks
Pieris Pharmaceuticals: Q1 Earnings Snapshot - Marketscreener.com
Wayne’s Palvella Therapeutics Completes Reverse Merger with Pieris Pharmaceutical - VISTA.Today
Palvella therapeutics director George Jenkins acquires $51,720 in shares By Investing.com - Investing.com Canada
Palvella therapeutics director George Jenkins acquires $51,720 in shares - Investing.com
Pieris Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2021 - Marketscreener.com
Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific - Marketscreener.com
Larimar Therapeutics Reports Promising Results for Friedreich’s Ataxia Treatment - MyChesCo
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 - Marketscreener.com
Pieris Pharmaceuticals, Inc. Announces Management Changes - Marketscreener.com
Pieris Pharmaceuticals, Inc. Appoints Julian Adams to its Board of Directors - Marketscreener.com
Pieris Pharmaceuticals, Inc. Appoints Claude Knopf as Senior Vice President and Chief Business Officer - Marketscreener.com
After losing AstraZeneca collab, Boston biotech opts for reverse merger - The Business Journals
Palvella Therapeutics Closes Merger with Pieris Pharmaceuticals - citybiz
Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of Cd228 X 4-1Bb Bispecific Molecule (Mabcalin Sgn-Bb228 (Prs-346) - Marketscreener.com
Pieris Pharmaceuticals: Q3 Earnings Snapshot - Marketscreener.com
PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc.PIRS - Marketscreener.com
0.47%
2.63%
大文字化:
|
ボリューム (24 時間):